Elevation Entered into an Exclusive License Agreement with CSPC to Develop and Commercialize EO-3021 (SYSA1801) for Solid Tumors
Shots:
- CSPC to receive a $27M up front & will also be eligible to receive ~$148M in development and regulatory milestones, ~$1.0B in commercial milestones along with royalties on net sales. Elevation Oncology will be responsible to develop and commercialize EO-3021 in all global territories outside of Greater China
- The collaboration will expand the pipeline to include two clinical stage precision oncology products & will use Elevation Oncology's expertise in genomically defined cancers incl. those with Claudin18.2 overexpression
- SYSA1801 is currently being studied in the P-I dose-escalation trial for CSPC in China & is expected to initiate a P-I clinical trial in the US in 2023
Ref: PRNewswire | Image: Elevation Oncology
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
